PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 153 filers reported holding PUMA BIOTECHNOLOGY INC in Q3 2016. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $7,847,000 | -55.4% | 255,602 | -2.5% | 0.98% | -55.4% |
Q3 2016 | $17,586,000 | +110.1% | 262,286 | -6.7% | 2.21% | +86.0% |
Q2 2016 | $8,371,000 | +43.3% | 280,985 | +41.3% | 1.19% | +54.1% |
Q1 2016 | $5,840,000 | -53.0% | 198,859 | +25.5% | 0.77% | -47.2% |
Q4 2015 | $12,424,000 | +20.3% | 158,475 | +15.6% | 1.46% | +22.0% |
Q3 2015 | $10,327,000 | -37.3% | 137,041 | -2.9% | 1.20% | -28.5% |
Q2 2015 | $16,476,000 | -51.8% | 141,123 | -2.5% | 1.67% | -50.4% |
Q1 2015 | $34,170,000 | +44.6% | 144,721 | +15.9% | 3.37% | +53.9% |
Q4 2014 | $23,626,000 | -2.0% | 124,826 | +23.5% | 2.19% | -3.0% |
Q3 2014 | $24,109,000 | +133.2% | 101,055 | -35.5% | 2.26% | +145.3% |
Q2 2014 | $10,339,000 | -60.3% | 156,649 | -37.4% | 0.92% | -62.7% |
Q1 2014 | $26,066,000 | +4.3% | 250,296 | +3.7% | 2.47% | +7.0% |
Q4 2013 | $24,994,000 | +66.4% | 241,419 | -13.8% | 2.31% | +65.3% |
Q3 2013 | $15,021,000 | -0.8% | 279,926 | -18.0% | 1.40% | -11.8% |
Q2 2013 | $15,149,000 | – | 341,417 | – | 1.58% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
HARVARD MANAGEMENT CO INC | 600,000 | $45,216,000 | 3.56% |
Avalon Global Asset Management LLC | 32,900 | $2,479,000 | 1.79% |
CORNERSTONE CAPITAL MANAGEMENT LLC | 495,145 | $37,314,000 | 1.58% |
BB BIOTECH AG | 521,991 | $39,337,000 | 1.25% |
WEATHERBIE CAPITAL, LLC | 137,041 | $10,327,000 | 1.20% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $428,527,000 | 1.19% |
TOBAM | 318,384 | $23,994,000 | 0.94% |
Orbimed Advisors | 1,195,500 | $90,093,000 | 0.91% |
Capital International Sarl | 109,405 | $8,245,000 | 0.74% |
CAPITAL INTERNATIONAL LTD /CA/ | 145,697 | $10,980,000 | 0.73% |